Table 1 Demographic, clinical and immunological variables associated with MVC-containing cART

Male sex, n (%)

15 (71)

16 (80)

0.525; 0.625 [0.147–2.659]

Age (years)

36 [31–44]

44 [39–48]

0.024; 0.892 [0.800–0.985]

0.878; 1.01 [0.87–1.18]

Nadir CD4⁺ T-cell count (cells/mm³)

294 [184–412]

264 [206–379]

0.539; 1.001 [0.997–1.005]

CD4⁺ T-cell count (cells/mm³)

703 [565–869]

725 [529–911]

0.775; 1.000 [0.997–1.002]

CD8⁺ T-cell count (cells/mm³)

781 [538–961]

596 [491–829]

0.109; 1.002 [1.000–1.004]

CD4⁺/CD8⁺ ratio

0.9 [0.6–1.2]

1.1 [0.9–1.6]

0.084; 0.309 [0.082–1.170]

0.086; 0.20 [0.03–1.26]

Time since diagnosis (months)

65 [32–212]

132 [67–235]

0.158; 0.995 [0.989–1.002]

Time on HIV-treatment (months)

46 [33–147]

120 [64–201]

0.057; 0.992 [0.984–1.000]

0.105; 0.99 [0.97–1.00]

Sexual transmission, n (%)

18 (86)

18 (90)

0.677; 1.500 [0.223–10.077]

Previous AIDS, n (%)

1 (5)

1 (5)

0.972; 0.950 [0.055–16.293]

Previous HCV coinfection, n (%)

4 (19)

1 (5)

0.199; 4.471 [0.454–44.011]

NRTI containing cART, n (%)*

4 (19)

14 (70)

0.002; 0.101 [0.024–0.430]

hsCRP (mg/l)

0.8 [0.5–1.1]

0.9 [0.6–1.5]

0.324; 0.612 [0.231–1.623]

% CD4⁺ naive

44.1 [34.5–55.6]

44.9 [33.7–50.1]

0.829; 0.995 [0.954–1.039]

% CD4⁺ RTE

78.0 [69.9–82.5]

69.3 [64.3–76.4]

0.016; 1.116 [1.021–1.220]

0.024; 1.20 [1.03–1.41]

% CD4⁺ central memory

29.4 [23.3–33.2]

28.3 [22.9–42.5]

0.752; 0.989 [0.926–1.057]

% CD4⁺ effector memory

20.0 [18.0–27.5]

22.0 [12.9–28.5]

0.968; 0.999 [0.936–1.065]

% CD4⁺ TemRA

2.4 [1.1–4.3]

1.6 [0.8–4.4]

0.873; 1.017 [0.831–1.243]

% CD4⁺ HLA-DR⁺

1.8 [1.0–2.0]

1.6 [1.1–2.3]

0.880; 1.066 [0.464–2.451]

% CD4⁺ Ki67⁺

2.4 [2.0–3.2]

2.2 [2.1–2.6]

0.219; 1.629 [0.748–3.547]

% CD4⁺ CD57⁺

4.8 [3.5–8.0]

4.47 [2.1–10.8]

0.879; 0.990 [0.873–1.124]

% CD4⁺ CD95⁺

55.0 [40.7–66.0]

54.4 [44.1–63.9]

0.590; 1.011 [0.971–1.052]

% CD4⁺ CD25^hiFoxP3⁺

1.2 [0.9–2.0]

1.5 [1.1–1.7]

0.992; 0.995 [0.358–2.765]

% CD4⁺ CD25^hiFoxP3⁺HLA-DR⁺

13.9 [9.9–21.6]

16.1 [12.2–22.1]

0.543; 0.973 [0.889–1.064]

% CD4⁺ CD25^hiFoxP3⁺ki67⁺

18.5 [13.5–25.2]

20.1 [17.6–25.0]

0.216; 0.930 [0.830–1.043]

% CD4⁺ CD25^hiFoxP3⁺CD39⁺

82.0 [41.7–88.2]

83.7 [81.2–85.1]

0.716; 1.005 [0.980–1.029]

% CD4⁺ CD25^hiFoxP3⁺CTLA4⁺

59.0 [46.2–65.2]

57.7 [47.8–69.2]

0.545; 0.986 [0.941–1.032]

% mDCs

0.5 [0.3–0.8]

0.8 [0.6–1.4]

0.042; 0.226 [0.054–0.949]

0.048; 0.16 [0.03–0.98]

% pDCs

0.2 [0.1–0.2]

0.2 [0.1–0.3]

0.529; 0.109 [0.000–108.297]